It is a liquid formulated with 9 herbs and has undergone many clinical trials. It has sold over 5 million bottles in Germany the last year. Iberogast has been used by natural health practitioners, doctors and patients for 40 years.
Iberogast is the #1 best selling product we have… and we sell almost 20,000 products!
The name Iberogast comes from it’s main component, Iberis amara, which has an anti-inflammatory effect.
How it Works:
-Digestive secretions are stimulated through the bitter receptors on the taste buds of the tongue.
-Peristalsis (the rhythmic contraction of the intestines)is regulated by exerting a relaxing or a stimulating effect on the intestinal smooth muscle.
-The lining of the stomach and intestines are protected by the stimulation of mucus production by mast cells (mucus-producing cells of the stomach and intestines) and inflammatory substances are prevented from forming within the intestinal tract.
-Excessive flatulence is prevented by reducing the formation of intestinal gases.
Also, available in single bottles.
Ingredients in Iberogast:
The bitter candytuft is an indigenous, herbal, white blooming plant which belongs to the Cruciferae family. The fresh plant extract of Iberis amara represents the prokinetic component in Iberogast®. It increases the tone of smooth gastro-intestinal muscles and accelerates gastro-intestinal peristalsis (Strathmann, 1983; Okpanyi, 1993). Extracts of Iberis amara are only contained in the medicine Iberogast®.
Angelica is a plant growing up to 2 m high and belongs to the Umbelliferae. The extract acts to promote digestion, to relieve cramps and to promote gastric juice production (monograph, 1990).
The genuine camomile is an indigenous plant growing to up to 50 cm high and which belongs to the Compositae family. The extract is anti inflammatory, antibacterial, cramp relieving and promotes wound healing (monograph, 1990).
The genuine caraway is an indigenous, mostly biennial, 30 – 100 cm high plant belong-ing to the Umbelliferae. The extracts act in a microbicidal manner and relieve cramps (monograph, 1990). It improves the tolerability of flatulence promoting foods (e.g. cabbage, beans).
Milk thistle fruit
Milk thistle is a 60 – 150 cm high Compositae with large, purple red flower heads. The extract acts in an hepatoprotective manner and stimulates the regeneration of liver cells (monograph, 1986).
Lemon Balm leaves
The melissa plant belongs to the labiates, grows to 30 – 70 cm high and emanates a strong lemon odour. The extract acts as a seda-tive and in an anti-flatulent manner (monograph, 1990).
The peppermint belongs to the labiates and is a 30 – 60 cm high plant which was first described in England in 1696. The extract acts in an anti-flatulent manner, relieves cramps and stimulates bile production (monograph, 1990).
Greater celandine is a 30 – 70 cm high indigenous plant which belongs to the poppy family. The extract acts to relieve cramps in bile ducts and in the gastro-intestinal tract (monograph, 1985).
Liquorice is a perennial (up to 15 years), 1 – 2 cm high shrub which belong to the papil-ionaceous flower plants. The extract shows a cramp-relieving action and accelerates the healing of stomach ulcers (monograph, 1991).
Other Ingredients: alcohol 31%.
Contains No: sugar, salt, yeast, wheat, gluten, corn, soy, dairy products, artificial coloring, artificial flavoring and preservatives. This product contains natural ingredients; color variations are normal.
Notes: Manufactured in Germany by Steigerwald GmbH
Caution: This product contains alcohol. The amount per dose is very small (less than 1/10th teaspoon). Use of this product above the labeled dosage is not recommended, especially by pregnant or nursing women, unless under the guidance of a health care practitioner.
Dosage for Iberogast:
Adults: take 20 drops three times daily.
Children age 6-12: take 15 drops three times daily.
Children age 3-6: take 10 drops three times daily.
Take before or during meals. Shake before using. Can be taken with your favorite drink (warm water is recommended).
Functional Gastrointestinal Relief
Two functional gastrointestinal conditions, perhaps related, are functional dyspepsia (FD) and irritable syndrome (IBS). Many patients with either of these conditions also experience symptoms of the other condition.
These conditions are similar in that symptoms are typically chronic in nature, may wax and wane, and may worsen following meals. Characteristically, these complaints are sporadic, poorly localized, and without consistent identifiable aggravating or relieving factors. Psychosocial stressors play a role in both ailments. In addition, diagnosing these disorders may be challenging and take some time; a detailed history is central to the diagnosis, and extensive testing is unlikely to be helpful except to rule out other disorders. The similarities between IBS and FD raise the issue as to whether they are just different manifestations of the same disorder or whether they represent distinct clinical entities.
3 My personal view is that they represent different points along a continuous spectrum that may generally termed functional gastrointestinal disorders.
Functional Dyspepsia (FD)
FD, previously known as non-ulcer dyspepsia, is a sensory and motility problem of the digestive tract, where sensation and peristalsis – the normal downward pumping and squeezing of the esophagus, stomach, and duodenum – are disturbed. This leads to what is sometimes called visceral hyperalgesia, or amplified sensation, especially of unpleasant feelings; and impaired distensibility or uncoordinated and even ineffectual emptying of the upper gut, with resulting symptoms of pain, fullness, and bloating and inability to finish full meals. Around 20-29% of Canadians have FD but only a small number will consult a doctor.
Irritable Bowel Syndrome (IBS)
IBS affects approximately 20% of the Canadian population. Symptoms include abdominal pain, bloating and gas, constipation and/or diarrhea, sometimes alternating between the two stool consistencies. Defecation usually temporarily relieves the abdominal discomfort. At present, many gastroenterologists classify IBS as a distinctly separate functional bowel disorder from dyspepsia. However, upper gastrointestinal (GI) function regularly affects lower GI tract function, and vice versa.4 A recent study found delayed gastric emptying in patients with overlapping IBS and FD symptoms, whereas patients with IBS alone had emptying rates similar to those of healthy controls.5
The prime goal of therapy for functional GI conditions is to alleviate the patient’s pain and discomfort and then to relieve secondary symptoms including bloating and upper abdominal fullness in patients with dyspepsia; and constipation, bloating, diarrhea, and urgency in patients with IBS. Education helps patients understand why their symptoms are occurring. Patients also benefit from reassurance that pathology that is more serious has been ruled out.
For more information on treating dyspepsia and IBS with dietary and lifestyle modifications and/or medications, please contact the CSIR office. This article is focusing on a phytopharmaceutical (plant medicine) consisting of plant extracts used to treat both the upper and lower GI conditions of functional dyspepsia and IBS, called Iberogast® (STW 5).